Immunosuppressant tied to higher skin cancer risk

Swedish researchers say there is evidence of a dose-response relationship.
HealthDay News

Methotrexate is associated with an increased risk for skin cancer, with evidence of a dose-response pattern, according to a study published in the British Journal of Cancer.

Dr Sam Polesie, from the University of Gothenburg in Sweden, and colleagues examined the association between use of methotrexate and the risk for basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and cutaneous malignant melanoma (CMM) in a nationwide Danish case-control study.